GlassScriptPhysician profile
Babatunde Ojo
NPI 1336125707
$5,744.39
in general payments reported to CMS, 2019-2025
21 companies · $928 in 2025
The $928 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $720 · 2021: $557 · 2022: $613 · 2023: $1,187 · 2024: $757 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,872.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,496.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $947.24 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $913.17 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $847.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $287.46 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Abbvie INC. | $224.08 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $167.80 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $160.96 | 2023-2024 | Nuedexta |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2019 | |
| Lilly USA, LLC | $101.00 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $100.10 | 2020-2024 | |
| Avanir Pharmaceuticals, INC. | $92.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.84 | 2021-2023 | Jardiance |
| Ironwood Pharmaceuticals, INC | $53.95 | 2022-2024 | |
| Exact Sciences Corporation | $36.77 | 2023-2024 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $26.03 | 2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $25.04 | 2023 | |
| Hikma Pharmaceuticals USA | $23.97 | 2020 | |
| Dexcom, INC. | $16.44 | 2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $15.03 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.58 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babatunde Ojo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.